Cardiovascular health, heart failure, atherosclerosis, and cardiac research
460 articles
A large target trial emulation finds sustained Mediterranean diet adherence substantially lowers cardiovascular risk compared to low-fat and AHA diets.
A new ML framework maps silent organ damage across heart, brain, and kidneys in 27,000 patients, outperforming standard BP measures for survival prediction.
A JACC progress report spanning 2000–2024 reveals persistent excess cardiovascular death rates among Black Americans despite decades of advances.
A major registry study finds mechanical CPR devices did not improve cardiac arrest survival or neurological outcomes at EMS agencies.
Scientists map a precise molecular chain linking falling NAD levels to lysosomal dysfunction, cardiolipin loss, and age-related heart failure — and show NAD restoration can reverse it.
A new AHA scientific statement outlines evidence-based strategies to optimize heart failure care for older adults navigating frailty, polypharmacy, and multimorbidity.
An 80-week Amgen-sponsored Phase 3 trial evaluated evolocumab's safety and efficacy in pediatric patients aged 10–17 with inherited high LDL cholesterol.
Inflammation and blood sugar levels that deviate from what BMI predicts can dramatically shift heart failure risk, even at identical body weights.
A Phase 2 trial tests whether a fixed-dose combination pill can safely lower LDL cholesterol in people with type 2 diabetes.
A Phase 3 trial pits monthly lerodalcibep against evolocumab in homozygous familial hypercholesterolemia patients over 24 weeks.
A landmark AHA scientific statement tackles inconsistent cardiovascular safety reporting in oncology trials with a unified framework.
Merck's CETP inhibitor anacetrapib was evaluated alongside statin therapy to assess LDL-C lowering and HDL-C raising in hypercholesterolemia patients.
